Two single arm trials of AKL-T01, a digital therapeutic for adolescents and adults with ADHD.

Caitlin A Stamatis^1,2, Deborah N Farlow³, Catherine Mercaldi³, Minny Suh³, Amanda Maple³, Antonia Savarese³, Ann Childress⁴, Raun D Melmed⁵, Scott H Kollins^3,6

¹Akili Interactive Labs, Boston, MA, USA. caitlin.stamatis@northwestern.edu.

²Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. caitlin.stamatis@northwestern.edu.

³Akili Interactive Labs, Boston, MA, USA.

⁴Center for Psychiatry and Behavioral Medicine, Las Vegas, NV, USA.

⁵Melmed Center/Cortica, Scottsdale, AZ, USA.

⁶Department of Psychiatry, Duke University School of Medicine, Durham, NC, USA.

PubMed PMC DOI PDF

Abstract

Inattention symptoms represent a key driver of functional impairment in ADHD and often persist into adolescence and adulthood, underscoring a need for novel treatments targeting attentional control. We evaluated AKL-T01-a digital therapeutic that is FDA-cleared for children 8-12 y with ADHD-in adolescents and adults with ADHD in two independent single-arm trials: STARS-ADHD-Adolescent, a 4-week tr…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.